AML is an aggressive blood cancer characterized by uncontrolled growth of immature myeloid cells (blasts) in the bone marrow, resulting in rapid bone marrow failure, reduced red blood cell and platelet production. 1 IDH1 mutations in AML are linked to poorer outcomes, including higher relapse and lower survival rates. 2 Ivosidenib is the first approved targeted oral therapy for IDH1-mutated AML, representing a major advancement in personalized treatment. 2 We invite you to join an International speaker program featuring distinguished experts Prof. Dr. Michael Heuser , Dr.
Rahul Bhargav , Dr. Kalashetty and Dr. Shrinidhi on July 4, 2025 , at 8:00 PM IST . Gain expert insights on the evolving landscape of Acute Myeloid Leukemia (AML) from clinical context and global perspectives to practical case discussions and multidisciplinary strategies for optimized care. We look forward to your…